Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-10-23
2007-10-23
Carlson, Karen Cochrane (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S399000
Reexamination Certificate
active
11410514
ABSTRACT:
The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.
REFERENCES:
patent: 4263279 (1981-04-01), Sela et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4801578 (1989-01-01), Monsigny et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4894225 (1990-01-01), Zimmerman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5032521 (1991-07-01), White et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5621083 (1997-04-01), Better et al.
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5851829 (1998-12-01), Marasco et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6197528 (2001-03-01), Wu et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6218165 (2001-04-01), Estell et al.
patent: 6306626 (2001-10-01), Rosenblum et al.
patent: 6309873 (2001-10-01), Torrens Madrazo et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6531133 (2003-03-01), Lorberboum-Galski et al.
patent: 6599505 (2003-07-01), Rosenblum
patent: 6639054 (2003-10-01), Alibhai et al.
patent: 6669938 (2003-12-01), Rosenblum et al.
patent: 6750329 (2004-06-01), Rosenblum et al.
patent: 2002/0090374 (2002-07-01), Yarkoni et al.
patent: 2003/0073163 (2003-04-01), Fernandez et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0134302 (2003-07-01), Fernandez et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0009477 (2004-01-01), Fernandez et al.
patent: 2004/0013691 (2004-01-01), Rosenblum
patent: 2005/0100528 (2005-05-01), Rosenblum
patent: 2005/0214307 (2005-09-01), Rosenblum
patent: B79527/87 (1988-04-01), None
patent: B82047/87 (1988-06-01), None
patent: A13017/88 (1988-09-01), None
patent: A21725/88 (1989-03-01), None
patent: A30753/89 (1989-08-01), None
patent: 1339798 (1998-04-01), None
patent: 0118365 (1984-03-01), None
patent: 0160446 (1985-04-01), None
patent: 0150126 (1985-07-01), None
patent: 0184369 (1985-11-01), None
patent: 0226418 (1986-12-01), None
patent: 0222360 (1987-05-01), None
patent: 0256714 (1988-02-01), None
patent: 0281070 (1988-09-01), None
patent: 0305967 (1989-03-01), None
patent: 0336631 (1989-10-01), None
patent: 0350230 (1990-01-01), None
patent: 0396387 (1990-11-01), None
patent: 0893493 (1999-01-01), None
patent: 1564666 (1978-01-01), None
patent: 2148299 (1985-05-01), None
patent: WO 00/34317 (2000-06-01), None
patent: 86121 (1981-07-01), None
patent: 62209098 (1986-12-01), None
patent: 190200 (1987-08-01), None
patent: WO 85/00974 (1984-08-01), None
patent: WO 86/05098 (1985-07-01), None
patent: WO 86/02945 (1986-05-01), None
patent: WO 87/00056 (1986-06-01), None
patent: WO 88/09343 (1988-12-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/00405 (1990-01-01), None
patent: WO 91/16071 (1991-10-01), None
patent: WO 94/26910 (1994-11-01), None
patent: WO 97/22364 (1997-06-01), None
patent: WO 97/46259 (1997-12-01), None
patent: WO 98/37901 (1998-09-01), None
patent: WO 99/40198 (1999-08-01), None
patent: WO 99/43840 (1999-09-01), None
patent: WO 99/45128 (1999-09-01), None
patent: WO 99/49059 (1999-09-01), None
patent: WO 99/51620 (1999-10-01), None
patent: WO 99/51766 (1999-10-01), None
patent: WO 00/26406 (2000-05-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/42179 (2000-07-01), None
patent: WO 02/42420 (2002-05-01), None
patent: WO 02/074979 (2002-09-01), None
patent: WO 03/002598 (2003-01-01), None
Ardekani et al., “Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies,”Current Therapeutic Res., 62:803-819, 2001.
Blick et al., “Phase I study of recombinant tumor necrosis factor in cancer patients,”Cancer Res., 47:2986-2989, 1987.
Bregman and Meyskens, “Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma,”J. Biol. Response Mod., 7:384-389, 1988.
Fitzgerald et al., “Why toxins!,”Seminars in Cancer Biology, 7:87-95, 1996.
Freeman and Mayhew, “Targeted Drug Delivery,”Cancer, 67:573-583, 1986.
Ghose and Blair, “The design of cytotoxic-agent-antibody conjugates,”Crit. Rev. Ther. Drug Carrier Syst., 3:263-359, 1987.
Hamawy et al., “Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies,”Transplantation, 68:693-698, 1999.
Krizan et al., “Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants,”Cancer Res., 45:4904-4909, 1985.
McGraw et al., “Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias,”Cancer Immunol. Immunother., 39:367-374, 1994.
Murray et al., “Radioimmunoimaging in Malignant Melanoma Patients With the Use of Indium-111-labeled Antimelanoma Monoclonal Antibody (ZME-018) to High-molecular-weight Antigen,”NCI Monogr., 3:3-9, 1987.
Oldham et al., “Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer,”Cancer, 54:2795-2806, 1984.
Rosenblum et al., “Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells,”Cancer Immunol. Immunother., 42:115-121, 1996.
Soule et al., “A human cell line from a pleural effusion derived from a breast carcinoma,”JNCI, 51:1409-1416, 1973.
Aboud-Pirak et al., “Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells,”Biochem. Pharmacol., 38:641-648, 1989.
Adams et al., “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281:1322-1326, 1998.
Aggarwal and Kohr, “Human tumor necrosis factor,”Methods in Enzymology, 116:448-456, 1986.
Alfthan et al., “Properites of single-chain antibody containing different linker peptides,”Protein Engineering; 8:725-731, 1995.
Alkan et al., “Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies,”J. Interferon Res., 4(3):355-3
Cheung Lawrence
Rosenblum Michael G.
Carlson Karen Cochrane
Fulbright & Jaworski L.L.P.
Research Development Foundation
LandOfFree
Modified proteins, designer toxins, and methods of making... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified proteins, designer toxins, and methods of making..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified proteins, designer toxins, and methods of making... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3881664